MAP2K7 and melanoma: which also saw lower use of BRAF/MEK inhibitors compared with ICIs, and a decline in the use of BRAF/MEK inhibitors after 2015 among a cohort of older patients diagnosed with advanced melanoma between 2012 and 2017 who received immunotherapy or targeted therapy.7